Cetuximab sensitizes CRC cells to CPT-11—a chemotherapy drug—by suppressing HSP27 activity by targeting the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway. This evidence concerns the gene HSPB3 and colorectal carcinoma.